APA (7th ed.) Citation

M, T., JS, W., N, S., SL, H., BE, G., D, M., . . . J, K. (2024). Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell reports. Medicine, 5(5), 101586. https://doi.org/10.1016/j.xcrm.2024.101586

Chicago Style (17th ed.) Citation

M, Tian, et al. "Preclinical Development of a Chimeric Antigen Receptor T cell Therapy Targeting FGFR4 in Rhabdomyosarcoma." Cell Reports. Medicine 5, no. 5 (2024): 101586. https://doi.org/10.1016/j.xcrm.2024.101586.

MLA (9th ed.) Citation

M, Tian, et al. "Preclinical Development of a Chimeric Antigen Receptor T cell Therapy Targeting FGFR4 in Rhabdomyosarcoma." Cell Reports. Medicine, vol. 5, no. 5, 2024, p. 101586, https://doi.org/10.1016/j.xcrm.2024.101586.